| Authors: |
Mascarenhas J; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. john.mascarenhas@mssm.edu., Gleitz HFE; Department of Developmental Biology, Erasmus Medical Center, Rotterdam, The Netherlands.; Oncode Institute, Erasmus Medical Center, Rotterdam, The Netherlands., Chifotides HT; Leukemia Department, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Harrison CN; Guy's and St Thomas' NHS Foundation Trust, London, UK., Verstovsek S; Leukemia Department, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Vannucchi AM; Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy., Rampal RK; Leukemia Service, Department of Medicine and Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA., Kiladjian JJ; Hôpital Saint-Louis, AP-HP, Université Paris Cité, Paris, France., Vainchenker W; Gustave Roussy, INSERM UMR1287, Université Paris-Saclay, Villejuif, France., Hoffman R; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Schneider RK; Department of Developmental Biology, Erasmus Medical Center, Rotterdam, The Netherlands.; Oncode Institute, Erasmus Medical Center, Rotterdam, The Netherlands.; Institute of Cell and Tumor Biology, RWTH Aachen University, Medical Faculty, Aachen, Germany., List AF; Precision BioSciences, Inc, Durham, NC, USA. |
